<DOC>
	<DOCNO>NCT01610765</DOCNO>
	<brief_summary>This study identify Novel Antiviral Drug could use treat baby Herpes Simplex Virus ( HSV ) central nervous system ( CNS ) disease . In study investigator identify best dose young child well identify additional safety information Novel Antiviral Drug .</brief_summary>
	<brief_title>A Safety Dose-Determining Study CMX001 In Infants With Neonatal Herpes Simplex Virus ( HSV ) Infection Involving Central Nervous System ( CNS Disease )</brief_title>
	<detailed_description>In study , pharmacokinetics safety Novel Antiviral Drug determine baby neonatal HSV CNS disease . The study conduct 18 academic medical center throughout United States . Young infant present virologic confirmation neonatal HSV infection evidence CNS involvement eligible study enrollment . Study Day 1 define day dose 1 Novel Antiviral Drug study medication administer .</detailed_description>
	<mesh_term>Herpes Simplex</mesh_term>
	<mesh_term>Central Nervous System Diseases</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Signed Informed Consent parent legal guardian study subject Virologically confirm HSV infection [ e.g. , positive culture , DNA detection polymerase chain reaction ( PCR ) , direct fluorescent antibody stain body site compartment ] Evidence CNS involvement HSV disease [ e.g. , CSF pleocytosis , positive CSF PCR testing , clinical electroencephalogram ( EEG ) seizure activity , neuroimaging abnormality ) Starting parenteral acyclovir therapy time initiation CMX001 study drug receive parenteral acyclovir therapy ≤ 72 hour start CMX001 study drug ≤ 6 week ( 42 day ) age time initial onset disease symptom sign Weight study enrollment ≥ 2,630 gram Gestational age ≥ 36 week delivery Mother test negative HIV follow pregnancy Imminent demise Disseminated skin/eye/mouth ( SEM ) neonatal HSV disease classification Gastrointestinal abnormality might preclude absorption oral medication ( e.g. , history necrotizing enterocolitis , gastroschisis , malrotation , etc . ) Birth weight &lt; 2,500 gram Birth weight &gt; 4,500 gram Grade 3 4 vomiting , utilizing DAIDS Toxicity Tables ( Appendix B ) Grade 3 4 diarrhea , utilizing DAIDS Toxicity Tables ( Appendix B ) Creatinine clearance &lt; 15 mL/min/1.73m2 Serum albumin &lt; 2.0 g/dL Alanine aminotransferase ( ALT ) ≥ 2.6times upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) ≥ 2.6times upper limit normal ( ULN ) Direct bilirubin &gt; 2 mg/dL Known immunodeficiency Known congenital infection ( e.g. , symptomatic congenital cytomegalovirus infection ; syphilis ; congenital toxoplasmosis ) Congenital heart disease ( e.g. , patent ductus arteriosus , Tetralogy Fallot , hypoplastic leave heart syndrome , AV canal , VSD , ASD , transposition great artery , hypoplastic right ventricle , truncus arteriosus , pulmonic stenosis , Ebstein anomaly , coarctation aorta , interrupt aortic arch , double outlet right ventricle , dilate cardiomyopathy ) Infants currently receive anticipate need treatment digoxin withhold duration CMX001 therapy Infants currently receive anticipate need treatment ketaconazole withheld duration CMX001 therapy Receipt investigation drug within 30 day prior enrollment Concurrent enrollment participation interventional research study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>98 Days</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>HSV</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>herpes</keyword>
	<keyword>neonate</keyword>
</DOC>